Alzheimer's Immunotherapy Program

In September 2009, JANSSEN Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, acquired substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP), including bapineuzumab. 
 
For information about AIP, including clinical trials, please contact:

JANSSEN Alzheimer Immunotherapy (Dublin)
Treasury Building
Lower Grand Canal Street
Dublin 2, Ireland
Telephone: +353.1.709.4900
Fax: +353.1.709.4950
 
JANSSEN Alzheimer Immunotherapy Research & Development, LLC (South San Francisco)
700 Gateway Blvd
South San Francisco, CA 94080
Telephone: +1 650 794 2500; +1 888 381 4595
Fax: +1 650 794 2504